In aneurysms normally chosen for surveillance, the endovascular technique slowed growth by 70% in the small phase I trial.

Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights. Q1 ...

Orange County is home to some of the hottest medical device and biotechnology companies, producing a range of drugs and ...

Tariff talk will continue in the second week of earnings season, but the updates could also shed light on trends and ...

Analysts are estimating that Edwards Lifesciences will report an earnings per share (EPS) of $0.59. The announcement from ...

Edwards Lifesciences Corporation ( NYSE: EW) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - ...

Adhering to the principles of evidence-based medicine, Venus Medtech has consistently conducted long-term follow-up studies ...

Piper Sandler upgraded Edwards Lifesciences (EW) to Overweight from Neutral with a price target of $80, up from $73. The firm sees a “better ...

Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

Thanks to healthcare reform, the hurdles to securing reimbursement and technology add-on payments have risen. Boston will need to invest more in clinical studies to demonstrate superiority of outcomes ...

Inc. (Stock Code: 2500.HK, hereinafter referred to as 'Venus Medtech' or the 'Company'), a global leader in structural heart therapies, has announced financial results for the year ended December 31, ...